biOasis Technologies Ord Shs BIOAF

Zacks on PLX:

[prophetoffactz]

We expect milestones to be due upon approval from partner Chiesi; however, these amounts have not been disclosed.

 

We update our valuation to reflect the approval of Elfabrio, increasing our probability of success to 100%. Along with sharecount modifications, this generates a price target of $16.00 per share, a greater than 5x upside from the latest closing price.

We are looking forward to an investor day in June that will identify the pathway forward for development candidates and we hope provide an early look at Chiesi’s early commercialization efforts. We are interested to see how the relationship with Chiesi will evolve and how new in-development candidates PRX-115 and PRX-119 will advance.

[unclepieman]

and what if ANYTHING will do for BTI?

[prophetoffactz]

You tell us. Chiesi identified Lysosomal Storage Disorders as a strategic area for growth. Its billion dollar licensing deal with Protalix for Fabry is Chiesi's flagship strategic asset in Lysosomal Storage. Chiesi also has other minor interests in Lysosomal Storage. Fabry has now been approved in Europe and the US. It is game on. The enzyme could benefit from delivery to the brain given the